Weak Phase III data have dealt a blow to Vectura’s hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease patients.

Immuno-oncology antibody company Leap Therapeutics has reverse merged with Israeli public wound care player Macrocure.

Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.

CTI BioPharma, still under a clinical hold enforced by the FDA back in February for its investigational JAK2 inhibitor candidate pacritinib, has posted new…

Since Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver and…

TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…

Medivation loses its VP after the Pfizer buy, Shanghai Pharma loses its chairman after only three months and Sarah Jessica Parker waves goodbye to Mylan…